{"id":67635,"date":"2026-06-08T14:32:57","date_gmt":"2026-06-08T06:32:57","guid":{"rendered":"https:\/\/flcube.com\/?p=67635"},"modified":"2026-06-08T14:32:58","modified_gmt":"2026-06-08T06:32:58","slug":"msd-launches-winrevair-sotatercept-in-china-first-activin-signaling-inhibitor-for-pulmonary-arterial-hypertension","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67635","title":{"rendered":"MSD Launches Winrevair (Sotatercept) in China \u2013 First Activin Signaling Inhibitor for Pulmonary Arterial Hypertension"},"content":{"rendered":"\n

Merck & Co., Inc.<\/strong> (MSD; NYSE: MRK<\/a>) announced the official commercial launch of Winrevair (sotatercept)<\/strong> in China, marking the introduction of the world’s first activin signaling inhibitor (ASI)<\/strong> for the treatment of pulmonary arterial hypertension (PAH)<\/strong>. The therapy, approved by Chinese regulators in February 2026, targets adult patients with WHO functional class II-III PAH (WHO Group 1) and represents the first etiological treatment addressing the root cause of disease progression.<\/p>\n\n\n\n

Regulatory Milestone & Indication Details<\/h2>\n\n\n\n
Parameter<\/th>Specification<\/th><\/tr><\/thead>
Drug Name<\/strong><\/td>Winrevair (sotatercept)<\/td><\/tr>
Approval Date<\/strong><\/td>February 2026 (China)<\/td><\/tr>
Indication<\/strong><\/td>Adult patients with WHO FC II-III PAH (WHO Group 1)<\/td><\/tr>
Therapeutic Class<\/strong><\/td>Activin Signaling Inhibitor (ASI) \u2013 first-in-class globally<\/td><\/tr>
Treatment Paradigm<\/strong><\/td>Etiological therapy targeting disease root cause vs. symptomatic management<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Mechanism of Action & Clinical Innovation<\/h2>\n\n\n\n